Sequenom secures IP for noninvasive genetic prenatal tests
This article was originally published in Clinica
Executive Summary
Sequenom has acquired exclusive rights in the US and certain European countries, including the UK, to intellectual property (IP) relating to noninvasive prenatal diagnostics held by Isis Innovation, the technology transfer company of the University of Oxford in the UK.